Unicycive Therapeutics (UNCY) Price to Book (2021 - 2026)

Unicycive Therapeutics (UNCY) has reported Price to Book for 6 consecutive years, with 2.45 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 40.14% year-over-year to 2.45; the trailing twelve-month figure through Jun 2026 stood at 2.45 (down 40.14% YoY), and the FY2025 full-year result was 3.04, down 57.6% from the prior year.
• Price to Book retreated to 2.45 in Q2 2026 per UNCY's latest filing, from 4.4 in the prior quarter.
• Across five years, Price to Book topped out at 8.7 in Q3 2023 and bottomed at 17.65 in Q4 2022.
• Historically, Price to Book has averaged 0.32 across 5 years, with a median of 1.36 in 2022.
• The sharpest annual moves came in 2022 and 2026: Price to Book plunged 1309.67% in 2022, then surged 2459.07% in 2026.
• Over 5 years, Price to Book stood at 17.65 in 2022, then jumped by 68.33% to 5.59 in 2023, then soared by 228.07% to 7.16 in 2024, then sank by 57.6% to 3.04 in 2025, then retreated by 19.21% to 2.45 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 2.45, 4.4, and 3.04 for Q2 2026, Q1 2026, and Q4 2025 respectively.